VPS25

VPS25 is a core subunit of the ESCRT-II complex that bridges ESCRT-I to ESCRT-III during multivesicular body biogenesis, functioning through two tandem winged-helix domains, the second of which directly engages the ESCRT-III subunit VPS20/CHMP6 to activate membrane budding and scission required for lysosomal degradation of ubiquitinated cargo such as EGFR and FGFR (PMID:15579210, PMID:19686684, PMID:15511219, PMID:16973552). In Drosophila, VPS25 acts as a tumor suppressor: its loss causes endosomal accumulation of Notch and Dpp receptors, ectopic activation of Notch, JAK-STAT, and Hippo signaling, and non-autonomous overgrowth that can progress to metastasis when apoptosis is blocked (PMID:16256743, PMID:16256745, PMID:16611691). VPS25 selectively modulates receptor tyrosine kinase trafficking in vertebrate development, as a hypomorphic mouse allele perturbs FGFR degradation and causes polydactyly without affecting SHH or WNT signaling (PMID:25373905). Beyond its canonical ESCRT role, VPS25 directly binds RNA through recognition of a polypurine (GA-rich) motif, revealing an additional molecular activity for ESCRT-II (PMID:29903915).

1. 2004 High

   Determining the atomic structure of VPS25 established that its two tandem winged-helix domains form the building block of ESCRT-II architecture, resolving how two copies of VPS25 integrate into the heterotetrameric ESCRT-II complex.

   Evidence X-ray crystallography at 3.1 Å resolution of isolated VPS25 and comparison with the ESCRT-II holocomplex structure

   PMID:15579210

   Open questions at the time

   • The functional significance of each winged-helix domain was not yet assigned
   • How VPS25 contacts downstream ESCRT-III was unknown
2. 2005 High

   Identification of the direct VPS25–CHMP6/VPS20 interaction established VPS25 as the ESCRT-II subunit responsible for recruiting and activating ESCRT-III, the central mechanistic step in multivesicular body formation.

   Evidence Purified recombinant protein pull-downs, co-immunoprecipitation, siRNA knockdown of EAP20 blocking EGFR lysosomal targeting, and VPS4-dependent endosomal recruitment assays in human cells

   PMID:15511219 PMID:16371348 PMID:16973552

   Open questions at the time

   • Structural basis of the VPS25–CHMP6 interface was not yet resolved
   • Whether ESCRT-II is essential or cargo-selective in mammalian cells was debated, as siRNA depletion gave inconsistent effects on EGFR degradation across studies
3. 2005 High

   Drosophila genetic studies revealed VPS25 as a tumor suppressor whose loss causes endosomal trapping of Notch and Dpp receptors, activating Notch, JAK-STAT, and Hippo pathways and driving non-autonomous overproliferation and metastatic behavior.

   Evidence Mosaic clonal analysis in Drosophila imaginal discs, epistasis with Notch, JAK-STAT (Unpaired), Hippo, JNK, and apoptosis pathways by two independent groups

   PMID:16256743 PMID:16256745 PMID:16611691

   Open questions at the time

   • Whether mammalian VPS25 loss produces analogous tumor-suppressive or signaling phenotypes was unknown
   • The relative contribution of each deregulated pathway to tumor phenotype was not resolved
4. 2009 High

   A 2.0 Å crystal structure of the VPS25 WH2–VPS20 complex, combined with in vitro reconstitution of budding/scission, demonstrated that ESCRT-II directly activates ESCRT-III-driven membrane remodeling through VPS25's second winged-helix domain.

   Evidence X-ray crystallography, reconstituted giant unilamellar vesicle budding assay, interface mutagenesis, in vivo cargo sorting in yeast

   PMID:19686684

   Open questions at the time

   • How membrane curvature and lipid composition influence the VPS25-VPS20 activation step was not addressed
   • Whether auxiliary factors modulate this interface in vivo remained open
5. 2014 High

   A hypomorphic mouse VPS25 allele showed that ESCRT-II exhibits receptor-selective trafficking control—specifically modulating FGFR but not WNT or SHH receptor degradation—explaining how partial ESCRT-II dysfunction causes a specific developmental defect (polydactyly) rather than generalized endosomal failure.

   Evidence ENU mutagenesis-derived and null mouse alleles, receptor trafficking and signaling assays in MEFs, limb development phenotyping

   PMID:25373905

   Open questions at the time

   • The molecular determinant that confers FGFR selectivity over other RTKs is unknown
   • Whether human VPS25 mutations cause analogous developmental phenotypes has not been reported
6. 2018 High

   Discovery that VPS25 directly cross-links to RNA and specifically recognizes a polypurine (GA-rich) motif expanded the functional repertoire of ESCRT-II beyond membrane trafficking, suggesting a role in RNA biology.

   Evidence UV cross-linking and CLIP-Seq in Xenopus egg extracts, in vitro reconstitution with purified ESCRT-II components

   PMID:29903915

   Open questions at the time

   • The physiological consequence of VPS25–RNA binding (e.g. RNA localization, stability, or translation) is not established
   • Whether RNA binding is conserved in mammalian cells and whether it intersects with endosomal trafficking is unknown
7. 2021 Medium

   VPS25 knockdown in human glioma cells demonstrated a pro-proliferative role for VPS25 in cancer, mediated at least partly through JAK-STAT signaling and cell cycle regulators (p21, CDK2, cyclin E), paralleling the JAK-STAT connection first identified in Drosophila.

   Evidence siRNA knockdown, flow cytometry for cell cycle and apoptosis, transcriptome sequencing, western blot in glioma cell lines

   PMID:34863175

   Open questions at the time

   • Direct mechanism linking VPS25 to JAK-STAT activation in mammalian cells (receptor identity, ubiquitination status) is not defined
   • Whether the glioma phenotype depends on ESCRT-II complex integrity or a moonlighting function of VPS25 is unresolved
8. 2025 Medium

   Recent studies extended VPS25's roles to neuronal autophagy and immune evasion: VPS25 knockdown in hippocampal neurons promoted autophagy flux and reduced apoptosis via JAK-STAT inhibition, while in HNSCC cells VPS25 promoted immune evasion through PVR upregulation and TIGIT signaling.

   Evidence AAV-mediated VPS25 silencing in rat hippocampus with behavioral and molecular readouts; siRNA knockdown in CAL27 cells with single-cell and spatial transcriptomics

   PMID:40149859 PMID:41448467

   Open questions at the time

   • Both studies are from single labs without independent replication
   • Whether VPS25's effects on autophagy and PVR expression require ESCRT-II complex function or alternative interactions is untested
   • The direct molecular link between VPS25 and PVR transcriptional regulation is undefined

• Key unresolved questions include: what physiological role VPS25's RNA-binding activity serves; how ESCRT-II achieves receptor-selective trafficking in mammals; and whether VPS25 loss-of-function mutations cause human disease.
• No human Mendelian disease linked to VPS25 mutations has been reported
• The structural basis for RNA substrate selectivity by VPS25 is unknown
• Comprehensive analysis of cargo selectivity for ESCRT-II in different mammalian tissues is lacking